Poly (lactic-co-glycolic acid)-encapsulated iodine-131 nanoparticles fabricated with rhTSH induce apoptosis and immobilization of thyroid cancer cells

Background Aggressive thyroid carcinoma (ATC) usually loses radioiodine avidity to iodine-131 (131I) due to the downregulation of sodium/iodide symporter (NIS). The expression of thyroid stimulating hormone receptor (TSHR) is more persistent than NIS and the administration of recombinant human thyroid stimulating hormone (rhTSH) promotes de novo NIS synthesis. Hence, exploring methods integrating 131I with rhTSH might be a feasible therapeutic strategy for selective delivery of 131I into thyroid cancer to fortify the effect of radioiodine ablation. Methods The 131I, poly (lactic-co-glycolic acid) (PLGA) and rhTSH were used to synthesize of the 131I-PLGA-rhTSH nanoparticles. The characteristics of the 131I-PLGA-rhTSH nanoparticles was determined using a light microscopy, scanning electron microscopy (SEM), autoradiography and immunofluorescence (IF) staining. The diameter of the 131I-PLGA-rhTSH nanoparticles was measured with a Mastersizer 3000, and the encapsulation efficiency (EF) of 131I in 131I-PLGA-rhTSH nanoparticles and the radioactivity of a single nanoparticle were determined. Then, the mouse tumor xenograft model was established, and the biodistribution and effect of 131I-PLGA-rhTSH nanoparticles on apoptosis of thyroid cance cells were investigated in vivo. Thereafter, the role of 131I-PLGA-rhTSH nanoparticles in cell viability using cell counting kit-8 and lactate dehydrogenase (LDH) release assays. Subsequently, the underlying mechanism of 131I-PLGA-rhTSH nanoparticles in reducing cell viability was assessed using immunostaining, boyden invasion assays and phalloidin staining. Results Our results showed that the method of developing nanoparticles-encapsulated 131I using poly (lactic-co-glycolic acid) (PLGA) and modified with rhTSH (131I-PLGA-rhTSH), was a feasible avenue for the integration of 131I and rhTSH. Meanwhile, the encapsulation efficiency (EF) of 131I-PLGA-rhTSH nanoparticles was approximately 60%, and the radioactivity of a single nanoparticle was about 1.1×10-2 Bq. Meanwhile, the 131I-PLGA-rhTSH nanoparticles were selectively delivered into, gradually enriched and slowly downregulated in xenograft tumor after the administration of 131I-PLGA-rhTSH nanoparticles through tail vein in mouse tumor xenograft model. Thereafter, the tumor weight was significantly reduced after the administration of 131I-PLGA-rhTSH nanoparticles. Subsequently, the application of 131I-PLGA-rhTSH nanoparticles facilitated apoptosis and attenuated immobilization via inhibiting F-actin assembling of FTC-133 cells. Conclusion The present study develops a suitable approach integrating 131I and rhTSH, and this strategy is a feasible regimen enhancing the effect of radioiodine ablation for the treatment of thyroid cancer.

[1]  Rong Hu,et al.  Transplantation of layer-by-layer assembled neural stem cells tethered with vascular endothelial growth factor reservoir promotes neurogenesis and angiogenesis after ischemic stroke in mice , 2022, Applied Materials Today.

[2]  A. Bockisch,et al.  Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  M. Schlumberger,et al.  Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer. , 2022, The New England journal of medicine.

[4]  C. Chiang,et al.  Polymer-Coated Nanoparticles for Therapeutic and Diagnostic Non-10B Enriched Polymer-Coated Boron Carbon Oxynitride (BCNO) Nanoparticles as Potent BNCT Drug , 2021, Nanomaterials.

[5]  D. Gheorghe,et al.  TNF-α May Exert Different Antitumor Effects in Response to Radioactive Iodine Therapy in Papillary Thyroid Cancer with/without Autoimmune Thyroiditis , 2021, Cancers.

[6]  A. Iovieno,et al.  Effect of Bevacizumab on the Viability and Metabolism of Human Corneal Epithelial and Endothelial Cells: An In Vitro Study , 2021, Translational vision science & technology.

[7]  A. S. Sogomonyan,et al.  PLGA Nanoparticles Decorated with Anti-HER2 Affibody for Targeted Delivery and Photoinduced Cell Death , 2021, Molecules.

[8]  A. De la Vieja,et al.  Radio-Iodide Treatment: From Molecular Aspects to the Clinical View , 2021, Cancers.

[9]  Ning Li,et al.  Downregulation of miR-146b-3p Inhibits Proliferation and Migration and Modulates the Expression and Location of Sodium/Iodide Symporter in Dedifferentiated Thyroid Cancer by Potentially Targeting MUC20 , 2021, Frontiers in Oncology.

[10]  Jia Liu,et al.  Biological implications of PTEN upregulation and altered sodium/iodide symporter intracellular distribution in resveratrol-suppressed anaplastic thyroid cancer cells , 2020, Journal of Cancer.

[11]  Weilin Xu,et al.  HLY78 Attenuates Neuronal Apoptosis via the LRP6/GSK3β/β-Catenin Signaling Pathway After Subarachnoid Hemorrhage in Rats , 2020, Neuroscience Bulletin.

[12]  J. Rosa-E-Silva,et al.  Impact of Bevacizumab on Experimentally Induced Endometriotic Lesions: Angiogenesis, Invasion, Apoptosis, and Cell Proliferation , 2020, Reproductive Sciences.

[13]  Jun Zhong,et al.  Actin Alpha 2 (ACTA2) Downregulation Inhibits Neural Stem Cell Migration through Rho GTPase Activation , 2020, Stem cells international.

[14]  O. Chinot,et al.  Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. , 2020, Cancer treatment reviews.

[15]  J. Eriksson,et al.  Nanoparticles carrying fingolimod and methotrexate enables targeted induction of apoptosis and immobilization of invasive thyroid cancer. , 2020, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[16]  L. Liao,et al.  Inhibition of microRNA-875-5p promotes radioiodine uptake in poorly differentiated thyroid carcinoma cells by upregulating sodium–iodide symporter , 2019, Journal of Endocrinological Investigation.

[17]  W. Chai,et al.  HMGB1-mediated autophagy regulates sodium/iodide symporter protein degradation in thyroid cancer cells , 2019, Journal of experimental & clinical cancer research : CR.

[18]  Yingli Wu,et al.  NES1/KLK10 and hNIS gene therapy enhanced iodine-131 internal radiation in PC3 proliferation inhibition , 2019, Frontiers of Medicine.

[19]  N. Li,et al.  Autophagy Inhibition Promotes Bevacizumab-induced Apoptosis and Proliferation Inhibition in Colorectal Cancer Cells , 2018, Journal of Cancer.

[20]  L. Jia,et al.  Effects of nuclear factor-κB on the uptake of 131iodine and apoptosis of thyroid carcinoma cells , 2018, Molecular medicine reports.

[21]  K. Makino,et al.  Hydrophobic boron compound-loaded poly(l-lactide-co-glycolide) nanoparticles for boron neutron capture therapy. , 2017, Colloids and surfaces. B, Biointerfaces.

[22]  L. Rosen,et al.  Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars , 2017, Targeted Oncology.

[23]  J. Abraham,et al.  Revisiting the Role of Bevacizumab in the Treatment of Breast Cancer. , 2017, Seminars in oncology.

[24]  C. Gedye,et al.  Targeting the TSH receptor in thyroid cancer. , 2017, Endocrine-related cancer.

[25]  K. Okazaki,et al.  Cytotoxic and genotoxic effects of 131I and 60Co in follicular thyroid cancer cell (WRO) with and without recombinant human thyroid‐stimulating hormone treatment , 2017, Environmental and molecular mutagenesis.

[26]  R. Diaz,et al.  The role of bevacizumab in the treatment of glioblastoma , 2017, Journal of Neuro-Oncology.

[27]  Han Xiao,et al.  Cell penetrating peptide of sodium-iodide symporter effect on the I-131 radiotherapy on thyroid cancer. , 2017, Experimental and therapeutic medicine.

[28]  L.M. Zhao,et al.  Iodine-131 treatment of thyroid cancer cells leads to suppression of cell proliferation followed by induction of cell apoptosis and cell cycle arrest by regulation of B-cell translocation gene 2-mediated JNK/NF-κB pathways , 2017, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[29]  T. Massoud,et al.  Tailored Nanoparticle Codelivery of antimiR-21 and antimiR-10b Augments Glioblastoma Cell Kill by Temozolomide: Toward a "Personalized" Anti-microRNA Therapy. , 2016, Molecular pharmaceutics.

[30]  H. Feng,et al.  Poly-L-ornithine promotes preferred differentiation of neural stem/progenitor cells via ERK signalling pathway , 2015, Scientific Reports.

[31]  Narayana M. Sekar,et al.  Polymer Nanoparticles Mediated Codelivery of AntimiR-10b and AntimiR-21 for Achieving Triple Negative Breast Cancer Therapy , 2015, ACS nano.

[32]  D. Lee,et al.  Relationship between Apoptosis Imaging and Radioiodine Therapy in Tumor Cells with Different Sodium Iodide Symporter Gene Expression , 2015, Molecular imaging.

[33]  P. Hou,et al.  Suppression of BRAF/MEK/MAP Kinase Pathway Restores Expression of Iodide-Metabolizing Genes in Thyroid Cells Expressing the V600E BRAF Mutant , 2007, Clinical Cancer Research.

[34]  O. Prante,et al.  In vitro studies on the signal transduction of thyroidal uptake of 18F-FDG and 131I-Iodide. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[35]  F. Miot,et al.  Correlation between the loss of thyroglobulin iodination and the expression of thyroid-specific proteins involved in iodine metabolism in thyroid carcinomas. , 2003, The Journal of clinical endocrinology and metabolism.

[36]  V. Lazar,et al.  Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. , 1999, The Journal of clinical endocrinology and metabolism.

[37]  D. Cui,et al.  Inhibiting β-catenin expression promotes efficiency of radioiodine treatment in aggressive follicular thyroid cancer cells probably through mediating NIS localization. , 2017, Oncology reports.

[38]  Trevor Coward,et al.  An In-Vitro Study , 2016 .

[39]  R. Latif,et al.  Characterization of thyrotropin receptor antibody-induced signaling cascades. , 2009, Endocrinology.